Caldera Therapeutics
Caldera Therapeutics is a biotech company engaged in the development of bispecific antibody CLD-423 for inflammatory bowel disease (IBD).
About Caldera Therapeutics
Caldera was founded in 2025 to advance innovative biologics in IBD, assembling a senior leadership team with deep experience in the discovery and development of IBD therapeutics and a proven track record of building biotechnology companies through to successful exits. Caldera Therapeutics is a biotech company engaged in the development of bispecific antibody CLD-423 for inflammatory bowel disease (IBD).
Company Facts
- Headquarters
- Cambridge
- Operating Status
- active
- Company Type
- for_profit
- IPO Status
- private
- Employees
- c_00001_00010
- Funding Stage
- early_stage_venture
- Total Funding
- $112,500,000
- Last Funding Type
- series_a
- Last Funding Date
- 2026-01-14
- Website
- calderatx.com
Industries & Categories
Biopharma, Biotechnology, Life Science
Social Links
Canonical: https://fsome.com/organization/caldera-therapeutics-29258 · For the full interactive profile (funding rounds, investors, team, portfolio, charts), please enable JavaScript.